These include dupilumab, an anti‐IL‐4R monoclonal antibody (mAb), mepolizumab, an anti‐IL‐5 mAb, and omalizumab, an anti‐IgE mAb which have now been approved for treating CRSwNP in the European Union.40, 41, 42. The gene discussed is IL5; the disease is chronic rhinosinusitis with nasal polyps.